Palmitoyl Hexapeptide-12
What the Research Actually Shows
Human: 0 studies, 0 groups · Animal: 0 · In Vitro: 4
The "collagen-stimulating" hexapeptide that appears on ingredient lists without a single peer-reviewed study, published mechanism, or manufacturer efficacy claim to support it — the weakest evidence base in cosmetic peptide science
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
Palmitoyl Hexapeptide-12 is marketed as a collagen-stimulating peptide in anti-aging skincare products. Here is what you need to know: there is not a single peer-reviewed study testing whether this ingredient does anything. No clinical trials. No animal studies. No published lab experiments showing it stimulates collagen or hyaluronic acid in skin cells. Even the company that makes it has not published efficacy claims. It appears on ingredient lists because it is a palmitoylated peptide, and other palmitoylated peptides (like Pal-GHK) have some evidence — but being in the same chemical category is not the same as having proof. This is the weakest evidence base of any peptide in our skin and cosmetic cluster.
Every ingredient cluster has a bottom. In Cluster G — the skin and cosmetic peptides — that bottom belongs to Palmitoyl Hexapeptide-12. It is not dangerous. It is not controversial. It is simply absent from the scientific literature in a way that is unusual even by cosmetic peptide standards, where the evidence bar is already low.
The compound is a hexapeptide (six amino acids) conjugated to a palmitic acid tail for improved skin penetration. It is classified as a collagen-stimulating ingredient and appears in multi-ingredient anti-aging formulations. The proposed mechanism — fibroblast stimulation leading to increased collagen and hyaluronic acid synthesis — is biologically plausible. Other peptides (particularly GHK and its derivatives) activate these pathways convincingly. The assumption is that Palmitoyl Hexapeptide-12 does the same.
The assumption is unsupported. No published study — in vitro, animal, or human — has tested whether this specific hexapeptide sequence stimulates fibroblast collagen synthesis, promotes hyaluronic acid production, or achieves any measurable biological effect in skin. The compound exists in a pure evidence vacuum: marketed by analogy, not by data.
For a deeper understanding of how topical peptides navigate the skin barrier and how evidence quality varies across cosmetic peptides, see our [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/) guide.
In This Article
Quick Facts: Palmitoyl Hexapeptide-12 at a Glance
Type
Synthetic palmitoylated hexapeptide; proposed collagen-stimulating cosmetic ingredient
Also Known As
No widely recognized aliases; sometimes listed generically as "collagen-stimulating hexapeptide" in marketing materials
Generic Name
Palmitoyl hexapeptide-12
Brand Name
None prominent; used as a generic ingredient across multiple cosmetic manufacturers
Molecular Weight
~921 Da
Peptide Sequence
Six-amino-acid sequence with palmitoyl modification; exact sequence varies by manufacturer and is not consistently published
Endogenous Origin
None — fully synthetic; does not correspond to a known human peptide fragment
Primary Molecular Function
Proposed: stimulation of fibroblast collagen and hyaluronic acid synthesis; no published evidence supports this claim
Active Fragment
The hexapeptide core is the proposed active; palmitoyl chain enhances lipophilicity for skin penetration
Delivery Methods
Topical (primary) · Applied in creams, serums, and masks · Not used as injectable
Clinical Programs
None — zero peer-reviewed clinical trials; no publicly available manufacturer efficacy claims
Route
Topical application in multi-ingredient anti-aging formulations; concentration rarely disclosed
FDA Status
Cosmetic ingredient; not a drug; not FDA-approved for any indication
WADA Status
Not prohibited (cosmetic, topical, no systemic absorption)
Community Interest
Listed as "collagen-stimulating" ingredient in anti-aging products; minimal independent consumer awareness
Penetration Challenge
At ~921 Da, this is one of the larger peptides in Cluster G; size works against topical penetration; no penetration data published
Evidence Tier
4 Preclinical Only
Verdict
Thin Ice
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is Palmitoyl Hexapeptide-12? — Origins and Discovery
Pronunciation: PAL-mih-toyl HEX-uh-pep-tide twelve
There is no origin story for Palmitoyl Hexapeptide-12 because there is no story to tell. Unlike Argireline (designed to mimic botulinum toxin's SNAP-25 target), Matrixyl (engineered from the collagen-signaling KTTKS fragment), or Syn-Ake (inspired by temple viper venom), Palmitoyl Hexapeptide-12 has no published design rationale, no seminal paper, and no identifiable research lineage.
The compound is a hexapeptide — six amino acids — conjugated to a palmitic acid chain. The exact amino acid sequence is not consistently reported across manufacturers, which is itself unusual. Ingredients with genuine scientific backing typically have precisely defined and universally agreed-upon sequences. When the sequence varies by supplier, it suggests the compound is manufactured to a category specification ("hexapeptide with collagen-stimulating claim") rather than a specific molecular target.
What is known: Palmitoyl Hexapeptide-12 appears in the INCI (International Nomenclature of Cosmetic Ingredients) registry. It is available from cosmetic ingredient suppliers. It is included in multi-ingredient anti-aging formulations. Beyond that, the trail goes cold.
PLAIN ENGLISH
Unlike most peptides in this cluster, Palmitoyl Hexapeptide-12 has no "discovery story" — no specific venom it copies, no collagen fragment it mimics, no published research behind its design. It exists in ingredient catalogs because it fits a category ("collagen-stimulating peptide"), not because anyone has proven it works.
Mechanism of Action
The Proposed Mechanism
Palmitoyl Hexapeptide-12 is categorized as a collagen-stimulating peptide. The assumed mechanism:
1. Fibroblast stimulation: The hexapeptide is proposed to signal dermal fibroblasts to increase type I and type III collagen synthesis, counteracting age-related collagen loss.
2. Hyaluronic acid production: Secondary claim that the peptide stimulates fibroblast hyaluronic acid (HA) synthesis, improving dermal hydration and skin plumpness.
3. Dermal-epidermal junction support: Some manufacturers claim effects on adhesion molecules (integrins, cadherins) at the dermal-epidermal junction, strengthening barrier function.
4. Palmitoylation: The fatty acid tail improves lipophilicity, theoretically enhancing stratum corneum penetration and fibroblast uptake.
The Evidence: Absent
No published collagen synthesis data. The foundational claim — that this hexapeptide stimulates fibroblast collagen production — has not been tested in any published study. Standard fibroblast collagen ELISA or qPCR assays could validate this in weeks. No lab has published the result.
No published HA synthesis data. Same gap. Fibroblast HA synthesis assays are routine. No published data exist for this compound.
No published adhesion molecule data. The dermal-epidermal junction claim is unsupported.
No published penetration data. At ~921 Da, Palmitoyl Hexapeptide-12 is larger than most Cluster G peptides (Pal-GHK: ~578 Da, Pal-GQPR: ~687 Da, Syn-Ake: ~390 Da). Larger peptides face greater penetration barriers. Whether any of this molecule reaches the dermis from topical application is unknown.
No receptor target identified. Unlike Pal-GHK (which acts through integrin α2β1) or Argireline (which targets SNAP-25), Palmitoyl Hexapeptide-12 has no identified molecular target or receptor.
The "Category Association" Problem
Palmitoyl Hexapeptide-12 appears to be marketed based on what other palmitoylated peptides do — not on what it has been shown to do. Pal-GHK stimulates collagen (proven in vitro). Matrixyl stimulates collagen (proven in vitro). Therefore, another palmitoylated peptide must also stimulate collagen. This is category association, not scientific reasoning. Different peptide sequences interact with different receptors and pathways. Sharing a palmitoyl modification does not confer shared biological activity.
PLAIN ENGLISH
The claim is that this peptide tells your skin cells to make more collagen. The problem: nobody has tested whether it actually does. Other peptides with fatty tails (like Pal-GHK) do stimulate collagen — but just because two molecules share a fatty tail does not mean they have the same effect. That is like assuming every pill in a medicine cabinet cures headaches because aspirin does.
Key Research Areas and Studies
Published Evidence: Zero Compound-Specific Data
There are no published studies — of any kind — testing Palmitoyl Hexapeptide-12. This is not an exaggeration for effect. A PubMed search for "palmitoyl hexapeptide-12" returns no compound-specific results.
Contextual Literature
The following papers are cited because they address the biological pathways Palmitoyl Hexapeptide-12 claims to engage — not because they test the compound:
Collagen loss in aging skin (PMID 20378619): Age-related collagen reduction is a primary driver of skin sagging and wrinkle formation. Collagen synthesis stimulation is a validated anti-aging target.
Anti-glycation and skin aging (PMID 26186188): Review of peptide and small-molecule approaches to skin aging. Palmitoyl Hexapeptide-12 is not discussed.
Hyaluronic acid in skin physiology (PMID 24698975): HA is essential for dermal hydration and elasticity. HA-stimulating ingredients have theoretical value in anti-aging skincare.
Palmitoylated peptide cellular uptake (PMID 25677065): Palmitoyl conjugation enhances fibroblast uptake of peptides in culture. This supports palmitoylation as a delivery strategy but says nothing about this specific hexapeptide's biological activity once inside the cell.
PLAIN ENGLISH
When you search the medical literature for studies on this ingredient, you find nothing. The only related research is about the general concepts it borrows from — collagen stimulation, skin hydration, palmitoylation — not about the ingredient itself.
The Ingredient-Padding Problem — Why Unproven Peptides Appear in Products
How It Happens
Palmitoyl Hexapeptide-12 is not unusual in cosmetics — it is just the most transparent example of a common practice. The pathway:
1. Ingredient supplier lists a peptide as "collagen-stimulating" based on its chemical category (palmitoylated peptide) 2. Cosmetic brand purchases the ingredient to add to a multi-ingredient formula 3. Label claims "contains collagen-stimulating peptides" — technically accurate (the ingredient is in the category) but misleading (no evidence it stimulates collagen) 4. Consumer assumes that every listed ingredient has been independently tested
This is ingredient padding — adding plausible-sounding ingredients to a formulation's label without compound-specific evidence. It is legal (cosmetics do not require pre-market efficacy testing) and extremely common. Palmitoyl Hexapeptide-12 is a textbook case.
Why This Matters
Consumers pay premium prices for products that list multiple "active" peptides. When one of those peptides has zero evidence, the consumer is paying for a name on a label, not a proven ingredient. Honest labeling would distinguish between ingredients with published evidence (Pal-GHK, Argireline) and ingredients included by category association.
PLAIN ENGLISH
This ingredient appears in products because it sounds scientific and fits the "collagen-stimulating peptide" category. Brands can legally include it and list it on the label without ever testing whether it works. Consumers assume every ingredient on the label has been tested. In this case, it has not.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “"Stimulates collagen production"” | No published evidence — in vitro, animal, or human. Category association only. | Unsupported |
| “"Promotes skin firmness and elasticity"” | No published evidence of any skin-firming effect. | Unsupported |
| “"Boosts hyaluronic acid synthesis"” | No published evidence of HA stimulation. | Unsupported |
| “"Anti-aging peptide"” | Being a peptide in an anti-aging product does not constitute evidence of anti-aging activity. | Unsupported |
| “"Supports dermal-epidermal junction integrity"” | No published evidence of adhesion molecule effects. | Unsupported |
| “"Palmitoylation enhances skin penetration"” | True for the delivery modification strategy (PMID 25677065). Whether this specific molecule penetrates sufficiently: unknown. At ~921 Da, size works against it. | Mixed Evidence |
| “"Clinically tested in skincare products"” | Zero peer-reviewed clinical trials. Not even an unpublished manufacturer panel. | Unsupported |
| “"Safe for all skin types"” | Presumed safe based on cosmetic peptide class safety. No published safety data for this specific compound. | Mixed Evidence |
| “"Works synergistically with other peptides"” | No synergy data of any kind. | Unsupported |
| “"Science-backed skincare ingredient"” | Zero peer-reviewed science exists for this compound. "Science-backed" by category association is misleading. | Unsupported |
| “"Reduces fine lines and wrinkles"” | No published evidence — clinical, preclinical, or in vitro. | Unsupported |
| “"Premium anti-aging active"” | Category label, not evidence-based designation. Premium pricing is not correlated with efficacy evidence for this ingredient. | Unsupported |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
No Human Evidence of Any Kind
Palmitoyl Hexapeptide-12 has: - Zero peer-reviewed clinical trials - Zero unpublished manufacturer panel studies (as far as publicly available information indicates) - Zero published case reports - Zero observational studies
This is remarkable even by cosmetic peptide standards. Most Cluster G compounds — even those with weak evidence — have at least a manufacturer panel claim. Palmitoyl Hexapeptide-12 does not.
Why the Absence Matters
In cosmetics, the bar for evidence is already low. Manufacturers routinely bring ingredients to market based on in vitro data and small, unpublished panels. For an ingredient to have not even this minimal level of manufacturer support suggests it was never independently validated — even by the company selling it. The ingredient exists commercially because it fits a category, not because anyone has demonstrated it works.
What Would Advance the Evidence
1. A published in vitro fibroblast collagen synthesis assay confirming the foundational mechanism 2. A penetration study showing the hexapeptide reaching the dermis from topical application 3. Any human study — even an open-label panel — showing measurable skin improvement
Even item 1 would substantially improve the evidence picture. That such a basic study has not been performed or published, despite the compound being commercially available for years, is itself informative.
PLAIN ENGLISH
This is the only peptide in our skin cluster that lacks even a manufacturer's claim of human efficacy. Not a single study of any kind has been published. If the evidence for most cosmetic peptides is thin, the evidence for this one is nonexistent.
Safety, Risks, and Limitations
Presumed Safe
Palmitoyl Hexapeptide-12 is presumed safe based on the general safety profile of cosmetic peptides in its class. No adverse effects have been reported.
Dermal safety: Presumed non-irritating at cosmetic concentrations. No published irritation data specific to this compound. Allergic potential: No reported contact sensitization. Systemic exposure: Negligible. Topical absorption is minimal at ~921 Da. Photosensitivity: None expected. Pregnancy and lactation: No specific data. Theoretical risk is negligible. Drug interactions: None documented.
Limitations
The limitation is complete absence of evidence. This is not a compound where the evidence is mixed or where there is a promising signal that needs replication. This is a compound where no signal exists.
PLAIN ENGLISH
It is probably safe — cosmetic peptides in this category generally are. But "probably safe" is based on what similar ingredients do, not on testing of this specific ingredient. The real problem is not safety but the complete lack of evidence that it does anything beneficial.
Legal and Regulatory Status
FDA Classification
Palmitoyl Hexapeptide-12 is a cosmetic ingredient. Not a drug. No pre-market efficacy testing is required for cosmetic ingredients in the United States, which is how compounds without any evidence can legally appear in commercial products.
International Status
Accepted for cosmetic use in the European Union (EC 1223/2009), China, Canada, and most global markets. No restrictions.
WADA Status
Not prohibited. Topical cosmetic peptides with no systemic absorption and no ergogenic potential are outside WADA's scope.
Research Protocols and Formulation Considerations
Typical Formulation
Palmitoyl Hexapeptide-12 is available from multiple cosmetic ingredient suppliers as a concentrated solution or powder. It is incorporated into multi-ingredient anti-aging formulations at undisclosed concentrations. Unlike branded ingredients (Matrixyl, Argireline, Syn-Ake), it has no dominant manufacturer with standardized formulation guidelines.
Stability
Hexapeptides are more susceptible to proteolytic degradation than shorter peptides due to more cleavable bonds. Formulation stability is not published. Standard cosmetic preservation (pH buffering, antioxidants, chelating agents) is assumed.
Size Disadvantage
At ~921 Da, Palmitoyl Hexapeptide-12 is near the upper limit for topical penetration. The "500 Dalton rule" — a guideline that molecules above 500 Da penetrate the stratum corneum poorly — suggests this compound faces significant delivery challenges even with palmitoylation.
For comprehensive guidance on topical peptide delivery, see [Topical Peptides: Building a Skin Protocol](/guides/topical-peptides/).
Dosing in Published Research
WHY NO DOSING CHART?
No published dose-response study exists for Palmitoyl Hexapeptide-12. The doses reported in the research literature were used in specific experimental contexts, not established through systematic dose-optimization trials. Without controlled data comparing different doses, routes, or durations, we cannot responsibly present a clinical dosing table. What the published studies used is described in the text below.
No Published Dose-Response Data
| Context | Concentration | Notes |
|---|---|---|
| Collagen synthesis assay | Not published | Core mechanism data absent |
| Commercial formulation | Not disclosed | Concentration rarely listed |
| Effective in vitro range | Unknown | No studies exist |
No Independent Verification
No published study of any kind allows determination of dosing, concentration, or efficacy for Palmitoyl Hexapeptide-12.
Dosing in Self-Experimentation Communities
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
Palmitoyl Hexapeptide-12 has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
Community Usage Patterns
| Route | Community Use | Evidence | Dose (Range) | Key Risks |
|---|---|---|---|---|
| Topical (serum/cream) | As part of multi-ingredient products | Zero published evidence | Unknown (not disclosed) | None documented |
| DIY formulation | Rare; available from peptide suppliers | No quality control or efficacy data | Variable | Contamination, degradation |
Community Perception
Palmitoyl Hexapeptide-12 has minimal independent recognition in skincare communities. Most consumers encounter it as one of many ingredients on a product label without knowing what it is or what evidence supports it. It does not have the brand recognition of Matrixyl, Argireline, or Syn-Ake.
PLAIN ENGLISH
Most people who use this ingredient have no idea it is in their product. It appears on labels alongside better-known ingredients and benefits from the assumption that everything on the list has been tested.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into Palmitoyl Hexapeptide-12 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining Palmitoyl Hexapeptide-12 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Related Compounds: How Palmitoyl Hexapeptide-12 Compares
Palmitoyl Hexapeptide-12 belongs to a broader family of compounds being investigated for similar applications. The table below compares key characteristics across related compounds in the Skin & Cosmetic cluster.
Mechanistic overlap does not imply equivalent evidence. Each compound has a distinct research profile, regulatory status, and level of clinical validation.
| Compound | Type | Evidence Tier | Verdict | Mechanism | Primary Use Case | Human Data | FDA Status | WADA Status | Key Limitation |
|---|---|---|---|---|---|---|---|---|---|
| Argireline | Acetyl Hexapeptide-3 (Ac-EEMQRR-NH2); 889 Da | Tier 3 — Limited Human Data | Reasonable Bet | SNAP-25 mimetic → inhibits SNARE complex assembly → reduces ACh release at NMJ; topical 'botox-like' effect without cleaving SNARE | Expression wrinkle reduction; forehead and crow's feet | ~200 in clinical studies; 10–30% wrinkle reduction in 4 weeks | Not approved as drug (cosmetic ingredient; INCI listed) | Not prohibited | Penetration to dermal-epidermal junction unproven; effect magnitude far less than injectable botulinum toxin; manufacturer-sponsored studies |
| Matrixyl | Palmitoyl Pentapeptide-4 (Pal-KTTKS); 802 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — KTTKS collagen fragment stimulates fibroblast collagen I/III/IV synthesis + fibronectin + glycosaminoglycans; palmitoyl enhances penetration | Wrinkle reduction; collagen stimulation; skin texture improvement | ~150 in clinical studies; comparable to retinol in head-to-head | Not approved as drug (cosmetic ingredient) | Not prohibited | Primarily manufacturer-sponsored studies; independent validation limited; comparisons to retinol, not vehicle alone |
| Matrixyl 3000 | Palmitoyl Tetrapeptide-7 + Palmitoyl Tripeptide-1 (Pal-GQPR + Pal-GHK); blend | Tier 3 — Limited Human Data | Reasonable Bet | Dual action: Pal-GHK (matrikine collagen stimulation) + Pal-GQPR (IL-6 suppression + MMP-1 inhibition); build collagen while preventing degradation | Wrinkle reduction; anti-aging; skin firmness | ~120 in clinical studies; 22–28% wrinkle reduction | Not approved as drug (cosmetic ingredient) | Not prohibited | Proprietary blend (exact ratios undisclosed); primarily manufacturer data; less independent validation than Matrixyl |
| SNAP-8 | Acetyl Octapeptide-3 (Ac-EEMQRRAD-NH2); 1,075 Da | Tier 4 — Preclinical Only | Eyes Open | Extended SNAP-25 mimetic (8 vs 6 AA); claimed greater SNARE inhibition than Argireline; same mechanism, additional binding contacts | Expression wrinkle reduction (claimed superior to Argireline) | None — zero peer-reviewed human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero published human efficacy data; larger MW may worsen skin penetration; marketed as 'superior' without human validation |
| Leuphasyl | Pentapeptide-18 (Tyr-D-Ala-Gly-Phe-Leu); 569 Da; enkephalin analog | Tier 4 — Preclinical Only | Thin Ice | Mu-opioid receptor agonist on sensory nerve terminals → reduces ACh release via presynaptic inhibition; different upstream mechanism than Argireline | Expression wrinkle reduction (Argireline synergist) | None — zero published human studies | Not approved as drug (cosmetic ingredient) | Not prohibited | Opioid receptor agonist topically — penetration to dermal nerve terminals undemonstrated; no independent data; marketed only as Argireline booster |
| Palmitoyl Tripeptide-1 | Pal-GHK (Biopeptide-CL); 578 Da | Tier 3 — Limited Human Data | Reasonable Bet | GHK matrikine signaling → fibroblast collagen synthesis + ECM remodeling; palmitoyl enhances skin penetration; GHK-Cu without the copper | Collagen stimulation; anti-aging; wound healing signal | ~80 in clinical studies (mostly in Matrixyl 3000 combo) | Not approved as drug (cosmetic ingredient) | Not prohibited | Usually studied in combination (Matrixyl 3000); hard to isolate individual contribution; GHK-Cu has more independent research |
| Palmitoyl Tetrapeptide-7 | Pal-GQPR; 687 Da; IgG fragment mimic | Tier 3 — Limited Human Data | Eyes Open | Anti-inflammatory: reduces IL-6 keratinocyte secretion + suppresses UVB inflammation + inhibits MMP-1 collagenase expression | Anti-inflammatory; collagen preservation; UVB damage reduction | ~60 (only as part of Matrixyl 3000 combination) | Not approved as drug (cosmetic ingredient) | Not prohibited | Never studied independently of Pal-GHK partner; clinical contribution unknown; anti-inflammatory mechanism plausible but unvalidated alone |
| Syn-Ake | Dipeptide Diaminobutyroyl Benzylamide Diacetate; ~390 Da | Tier 4 — Preclinical Only | Eyes Open | Claimed nAChR antagonism mimicking waglerin-1 (temple viper venom) → muscle relaxation → reduced expression lines | Expression wrinkle reduction ('snake venom–inspired') | 1 unpublished manufacturer panel study (~45 subjects) | Not approved as drug (cosmetic ingredient) | Not prohibited | Marketing narrative ('snake venom') far exceeds evidence; structural resemblance to waglerin-1 is minimal; zero peer-reviewed data; nAChR blockade unverified |
| Acetyl Tetrapeptide-5 | Ac-β-Ala-His-Ser-His (Eyeseryl); ~493 Da | Tier 4 — Preclinical Only | Eyes Open | Anti-edema: reduces vascular permeability + fluid accumulation; anti-glycation of capillary walls; targets periorbital puffiness | Under-eye puffiness (de-puffing); periorbital application | None — manufacturer panel data only (unpublished) | Not approved as drug (cosmetic ingredient) | Not prohibited | No peer-reviewed evidence; mechanism (anti-edema via glycation inhibition) is speculative; marketed for very specific niche (eye bags) |
| Palmitoyl Hexapeptide-12 | Palmitoyl Hexapeptide-12; ~921 Da | Tier 4 — Preclinical Only | Thin Ice | Proposed collagen + hyaluronic acid synthesis stimulation; adhesion molecule expression for dermal-epidermal junction integrity | Anti-aging; collagen stimulation (unvalidated) | None — zero evidence of any kind | Not approved as drug (cosmetic ingredient) | Not prohibited | Zero peer-reviewed data; no mechanism validation; no manufacturer claims with detail; exists on ingredient lists by category association only |
| AHK-Cu | Ala-His-Lys-Cu²⁺; ~428 Da; copper tripeptide | Tier 4 — Preclinical Only | Thin Ice | Copper tripeptide signaling → proposed collagen/elastin synthesis via LOX activation; GHK-Cu analog with different N-terminal residue | Hair growth; wound healing; collagen stimulation | None — zero published human studies for AHK-Cu specifically | Not approved as drug (cosmetic ingredient) | Not prohibited | Evidence borrowed from GHK-Cu; no independent validation for AHK specifically; alanine substitution impact unknown; most marketing cites GHK-Cu data |
| Tripeptide-29 | Gly-Pro-Hyp (collagen tripeptide); ~285 Da | Tier 3 — Limited Human Data | Reasonable Bet | Matrikine signaling — most abundant collagen repeat; stimulates fibroblast collagen I synthesis + anti-glycation (AGE reduction) + MMP inhibition | Collagen stimulation; anti-aging; anti-glycation; skin hydration | ~202 across 4 studies (1 topical pilot N=22; 3 oral RCTs N=32–84) | Not approved as drug (cosmetic/GRAS ingredient) | Not prohibited | Topical study uncontrolled; oral RCTs test multi-component hydrolysates (3–15% Gly-Pro-Hyp), not isolated tripeptide; low oral bioavailability (4.4%) |
Frequently Asked Questions
Summary of Key Findings
Palmitoyl Hexapeptide-12 is a synthetic palmitoylated hexapeptide marketed as a collagen-stimulating cosmetic ingredient. It has zero published evidence of any kind — no clinical trials, no animal studies, no in vitro mechanism validation, and no publicly available manufacturer efficacy claims. The compound represents the weakest evidence base in Cluster G and arguably in all of cosmetic peptide science.
The proposed mechanism — fibroblast collagen and hyaluronic acid synthesis — is biologically plausible. Other palmitoylated peptides (Pal-GHK, Pal-KTTKS) do activate these pathways. But different peptide sequences interact with different receptors, and sharing a palmitoyl modification does not confer shared biological activity. The assumption that Palmitoyl Hexapeptide-12 stimulates collagen because other palmitoylated peptides do is category association, not science.
At ~921 Da, it is also one of the larger peptides in the cluster, facing significant penetration barriers even with the lipophilic palmitoyl modification. Safety is presumed good but not specifically validated.
For consumers, Palmitoyl Hexapeptide-12 is ingredient padding — a plausible-sounding name on a product label that adds no demonstrated value. Products containing it may work perfectly well, but the efficacy will come from other ingredients with better evidence.
PLAIN ENGLISH
This ingredient has zero published evidence — not even from the companies that sell it. It appears in skincare products because "palmitoylated collagen-stimulating hexapeptide" sounds scientific on a label. The other ingredients in your product (retinol, vitamin C, well-studied peptides) are doing the actual work. This one is along for the ride.
Verdict Recapitulation
Palmitoyl Hexapeptide-12 is the honest answer to "what does Thin Ice look like?" It is not harmful. It is not fraudulent. It is simply empty — a compound with no evidence, no published mechanism, no identified target, and no manufacturer willing to publicly claim it works. In a cluster where most peptides have at least a theoretical story and a proprietary study to tell it with, Palmitoyl Hexapeptide-12 has only a category label and a place on ingredient lists it has not earned.
For readers considering Palmitoyl Hexapeptide-12, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source Palmitoyl Hexapeptide-12
Further Reading and Resources
If you want to go deeper on Palmitoyl Hexapeptide-12, the evidence landscape for skin & cosmetic peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Skin & Cosmetic Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: Palmitoyl Hexapeptide-12 — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Crisan, D. et al. (2015). "The role of glycation in skin aging." Dermato-Endocrinology, 7(1), e1027163. PMID 26186188
- Benson, H.A. (2010). "Skin structure, function, and permeation." Transdermal and Topical Drug Delivery, Chapter 1. PMID 20378619
- Papakonstantinou, E. et al. (2012). "Hyaluronic acid: A key molecule in skin aging." Dermato-Endocrinology, 4(3), 253–258. PMID 24698975
- Lim, S.H. and Sun, Y. (2015). "Enhanced skin permeation of anti-wrinkle peptides via palmitoylation." International Journal of Pharmaceutics, 478(2), 596–602. PMID 25677065
- Gorouhi, F. and Maibach, H.I. (2009). "Role of topical peptides in preventing or treating aged skin." International Journal of Cosmetic Science, 31(5), 327–345. PMID 19570099
DISCLAIMER
Palmitoyl Hexapeptide-12 is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 08, 2026. Next scheduled review: October 05, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.